Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GHZ339 · 1 trial · 1 indication
EASI will be used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.
| Arm | Type | Description |
|---|---|---|
| GHZ339 Dose A | EXPERIMENTAL | Participants who will receive GHZ339 at dose A during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2 |
| GHZ339 Dose B | EXPERIMENTAL | Participants who will receive GHZ339 at dose B during Treatment Period 1 will receive GHZ339 at dose B during Treatment Period 2 |
| GHZ339 Dose C | EXPERIMENTAL | Participants who will receive GHZ339 at dose C during Treatment Period 1 will receive GHZ339 at dose C or A during Treatment Period 2 |
| GHZ339 Dose D | EXPERIMENTAL | Participants who will receive GHZ339 at dose D during Treatment Period 1 will receive GHZ339 at dose D or A during Treatment Period 2 |
| Placebo | PLACEBO_COMPARATOR | Participants who will receive placebo during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2 |
| Name | Type | Description |
|---|---|---|
| GHZ339 | DRUG | GHZ339 administered at dose A, B, C and D |
| Placebo | DRUG | Matching placebo |
Key Inclusion Criteria of the master protocol: * Able and willing to sign the informed consent (IC) * Patients with a diagnosis of AD and onset of disease for at least 1 year * Moderate to severe AD Key Exclusion Criteria of the master protocol: * Participants with a clinically significant medica...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
GHZ339 is an investigational small molecule being studied for the treatment of moderate to severe atopic dermatitis. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in a randomized, double-blind, placebo-controlled platform study.
GHZ339 is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker NVS. The company is conducting a Phase 2 clinical trial to evaluate the efficacy and safety of GHZ339 in patients with moderate to severe atopic dermatitis.
GHZ339 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting participants to assess the drug's efficacy and safety in patients with moderate to severe atopic dermatitis.
GHZ339 is being studied in a single Phase 2 clinical trial registered as NCT06947993. This trial is a randomized, double-blind, placebo-controlled platform study evaluating the efficacy and safety of investigational compounds in patients with moderate to severe atopic dermatitis. The trial is currently recruiting and aims to enroll 224 participants.
The GHZ339 clinical trial, NCT06947993, is a Phase 2, randomized, double-blind, placebo-controlled study. It is designed to evaluate the efficacy and safety of GHZ339 in patients with moderate to severe atopic dermatitis. The trial is actively recruiting 224 participants aged 18 years and older across multiple countries.
GHZ339 is an investigational small molecule developed by Novartis AG for atopic dermatitis. No alternative names for GHZ339 have been disclosed in the clinical trial information. It is currently in Phase 2 development and is not yet approved for any use.